Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non‐small cell lung cancer-Reference-Cited by-同舟云学术

Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non‐small cell lung cancer

Published:2019-10-24 Issue:1 Volume:250 Page:19-29
ISSN:0022-3417
Container-title:The Journal of Pathology
language:en
Short-container-title:J. Pathol.

Author:

Alborelli Ilaria¹^ORCID,Leonards Katharina¹^ORCID,Rothschild Sacha I²³,Leuenberger Laura P¹^ORCID,Savic Prince Spasenija¹,Mertz Kirsten D⁴,Poechtrager Severin⁴,Buess Martin⁵,Zippelius Alfred²³,Läubli Heinz²³,Haegele Jasmin¹,Tolnay Markus¹,Bubendorf Lukas¹,Quagliata Luca¹,Jermann Philip¹^ORCID

Affiliation:

1. Department of Medical Genetics and Pathology University Hospital Basel Basel Switzerland

2. Laboratory of Cancer Immunology, Department of Biomedicine University Hospital Basel Basel Switzerland

3. Department of Medical Oncology, Department of Internal Medicine University Hospital Basel Basel Switzerland

4. Department of Pathology Cantonal Hospital Baselland Liestal Switzerland

5. Department of Medical Oncology St. Claraspital Basel Switzerland

Funder

Thermo Fisher Scientific

Bristol-Myers Squibb

Publisher

Wiley

Subject